UBS has given Siemens Healthineers a "Neutral" rating with a price target of €53.
According to analyst Graham Doyle, the first-quarter results for the medical technology company are expected to be satisfactory, but there are still risks associated with the overall performance for 2025.
Doyle's revenue forecast for the first quarter is slightly higher than the consensus, and he expects the adjusted operating profit (EBIT) to be 2% above the average estimate.
These insights were shared in a study released on January 14, 2025, which highlights a cautious outlook for the company due to ongoing uncertainties.